Biopharma Co. Escapes Investor Suit Over Drug Approval Lies

By Sydney Price · October 29, 2024, 6:36 PM EDT

Biopharmaceutical company Spero Therapeutics Inc. has escaped a proposed investor class action accusing it of concealing warning signs that it would not secure regulatory approval of one of its drugs, with...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re Spero Therapeutics, Inc. Securities Litigation

Case Number

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

May 26, 2022

Recent Articles By Sydney

November 21, 2024
SEC Denied Civil Penalties Over Pot Pill Exec's 'Inexperience'
November 15, 2024
Healthcare Co. PACS Made False Claims Before IPO, Suit Says
November 13, 2024
Biotech Brass Misled Investors About Cancer Drugs, Suit Says
October 29, 2024
Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
October 17, 2024
Acadia Hid Wrongful Detainment Of Patients, Investor Claims
September 25, 2024
Feds Urge Judge Not To Ax Novel Insider Trading Conviction
September 24, 2024
Philips Must Face Investor Suit Over FDA Compliance Issues
July 18, 2024
Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
July 15, 2024
Walgreens Investor Sues Over Challenged Pharmacy Division
July 10, 2024
Skin Care Tech Co. Says Suit Shows 'Rough' Year, Not Fraud